“The tropism of natural AAV serotypes is limited,” he says. “They also tend to infect the liver, which can cause severe side effects in some cases.” Improving AAV tropism could offer ...

2). The company is proceeding with additional capsid campaigns derived from AAV9, AAV5, and other AAV serotypes to identify novel capsids optimized for AAV delivery for specific therapeutic ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adenoassociated virus (AAV) serotypes 2 and 8, enabling determination of capsid ...

Asimov, the synthetic biology company advancing the design and production of therapeutics, today announced the launch of the ...